Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled, A Multicenter, Randomized, Double-blind, Placebo-controlled, 3 Parallel Groups, Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Oltipraz in Patients With Non-alcoholic Fatty Liver Disease (Except Liver Cirrhosis)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Mar 2017
Price :
$35
*
At a glance
- Drugs Oltipraz (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- Sponsors PharmaKing
- 22 Feb 2017 Primary endpoint of change in quantity of liver fat concentration assessed by MRS has been met, according to results published in the Alimentary Pharmacology and Therapeutics.
- 22 Feb 2017 Results published in the Alimentary Pharmacology and Therapeutics
- 22 Mar 2014 New trial record